DOCSLIB.ORG

Dual Inhibition of Jak2 and STAT5 Enhances Killing of Myeloproliferative Neoplasia Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dual Inhibition of Jak2 and STAT5 Enhances Killing of Myeloproliferative Neoplasia Cells Letters to the Editor 1407 8 Yin W, Rossin A, Clifford JL, Gronemeyer H. Co-resistance to retinoic acid and 12 Green CL, Evans CM, Zhao L, Hills RK, Burnett AK, Linch DC et al. The prognostic TRAIL by insertion mutagenesis into RAM. Oncogene 2006; 25: 3735 -- 3744. significance of IDH2 mutations in AML depends on the location of the mutation. 9 Jenkins RB, Wrensch MR, Johnson D, Fridley BL, Decker PA, Xiao Y et al. Distinct Blood 2011; 118: 409 -- 412. germ line polymorphisms underlie glioma morphologic heterogeneity. Cancer 13 Boissel N, Nibourel O, Renneville A, Huchette P, Dombret H, Preudhomme C. Genet 2011; 204: 13 -- 18. Differential prognosis impact of IDH2 mutations in cytogenetically normal acute 10 Rice T, Zheng S, Xiao Y, Decker PA, McCoy LS, Smirnov I et al. Associations of myeloid leukemia. Blood 2011; 117: 3696 -- 3697. glioma risk loci by IDH mutation status. NeuroOncology 2011; 13(Suppl 3): iii27. 14 Patnaik MM, Hanson AA, Hodnefield JM, Lasho T, Finke C, Knudson RA et al. 11 Sanson M, Hosking FJ, Shete S, Zelenika D, Dobbins SE, Ma Y et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum Mol Genet syndromes: a Mayo Clinic study of 277 patients. Leukemia 2011; e-pub ahead of 2011; 20: 2897 -- 2904. print 28 October 2011; doi:10.1038/leu.2011.298. Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells Leukemia (2012) 26, 1407--1410; doi:10.1038/leu.2011.338; the principal effect of pimozide in these MPN cell lines is the published online 2 December 2011 inhibition of STAT5 phosphorylation. Three lines of evidence suggest that pimozide is not functioning as a classic kinase inhibitor. First, pimozide does not inhibit Jak family kinases in an isolated in vitro kinase assays (Table 1). Myeloproliferative neoplasms (MPNs) are a group of clonal Second, its pattern of inhibition of substrate phosphorylation disorders that arise from the transformation of hematopoietic catalyzed by extracts from Jak2 V617F-expressing cells using the stem cells. In 2005, several groups reported a single acquired point PamChip tyrosine kinase microarray system (PamGene, Den Bosch, mutation in the Janus kinase 2 (Jak2) gene in the majority of Netherlands)11 is clearly distinct from that mediated by a Jak patients with Philadelphia chromosome (Ph)-negative MPN.1 The inhibitor (including no inhibition of the phopshorylation of the mutation is believed to have a critical role in the pathogenesis of Jak2 peptide by pimozide; Figure 1b). Pimozide did inhibit these disorders,2,3 and it has been suggested that most patients phosphorylation of a peptide derived from Jak1, though this harbor mutations (some of which remain to be identified) that likely occurred through an indirect mechanism. Finally, other potentially serve as a molecular target for selective Jak2 inhibition.4 signaling pathways downstream of Jak2, such as the phosphor- Although small molecule Jak2 inhibitors are entering clinical trials, ylation of extracellular signal-regulated kinase mitogen-activated their ultimate efficacy is unclear.5 In addition to the concern of protein kinases (MAPK) are not inhibited by pimozide (as they are insufficient inhibition of mutated Jak2 in vivo or the emergence of with Jak inhibitor 1) in BAFEJ and HEL cells, and actually show a resistance through activation of complementary pathways, many small but reproducible increased activity (Figure 1c). This finding is MPNs contain other mutational events (for example, mutation in similar to that seen in cells transformed with BCR/ABL,10 and may exon12 of Mpl,6 or the KIT D618V mutation in patients with reflect a loss of a negative regulator of MAPK signaling that is systemic mastocytosis7), and thus are not sensitive to Jak inhibitors. STAT5 dependent.12 Although the exact mechanism by which Therefore, the development of inhibitors to common mediators of pimozide inhibits STAT5 phosphorylation is being elucidated, it diverse signaling pathways in this disease is very desirable. may involve direct effects on STAT5 or on a negative regulator of One convergence point of these pathways is the transcription STAT5 activation rather than by targeting a kinase. factor STAT5. STAT5 regulates the expression of genes controlling Consistent with the central role of STAT5 activation in driving key events such as cell cycle progression and survival. Thus, expression of genes underlying the malignant nature of these continuous STAT5 activation drives increased expression of these cells, inhibition of STAT5 phosphorylation by pimozide also led genes that directly contribute to leukemogenesis. Continued to a decrease in expression of STAT5 target genes (Figure 1d). STAT5 activation appears to be necessary for tumor cell survival,8 Significantly, these include two important pro-survival genes, although normal cells are generally tolerant to the loss of STAT5 Bcl-xl and Mcl1. Bcl-xl appears to be a key mediator in promoting function. Consequently, STAT5 is an attractive target for cancer Jak2-mediated survival in SET2 cells13 as inhibition of Jak2 signaling therapy. Increasing evidence indicates that STAT5 activation is blocked STAT5-mediated regulation of Bcl-xl mRNA level and required for Jak2 V617F-mediated transformation.9 As STAT5 is a reduced its protein expression. Mcl1 is also a critical survival factor critical mediator of the effects of Jak2 V617F, the development of in MPN cells. Specific STAT5-docking domains have a major role in drugs that inhibit this transcription factor holds promise as a inducing Mcl1 expression driven by a mutated FLT3 containing an treatment for MPN. Furthermore, the dual inhibition of both STAT5 internal tandem duplication (FLT3-ITD), a mutation found in about and Jak2 may yield better disease control. 20% of acute myelogenous leukemia patients, independent of We previously identified the neuroleptic drug pimozide as an JAK2 activation.14 inhibitor of STAT5 transcriptional function in a cell-based screen.10 Given that pimozide inhibits STAT5 tyrosine phosphorylation In the present study, we evaluated the effect of pimozide alone and decreases STAT5 target genes expression, we next deter- and in combination with a Jak2 inhibitor on the biology of mined whether pimozide also affects the viability of cells with myeloproliferative cell lines. We examined a model system, Ba/F3 activating mutations of Jak2. Pimozide caused a dose-dependent cells that had been reconstituted with erythropoietin receptor and decrease in viability of the three cell lines, with IC50 (half maximal the mutant form of Jak2 (BAFEJ), as well as the HEL and SET2 inhibitory concentration) values ranging from 4 mM for BAFEJ and human leukemia cell lines that endogenously express Jak2 V617F. SET2 to 10 mM for HEL cells (Figure 1e and data not shown). As Treatment of each cell line with pimozide led to a decrease in expected, pimozide also inhibits survival of parental Ba/F3 cells, tyrosine phosphorylation of STAT5 (Figure 1a and data not which are known to be dependent on STAT5. shown). Reflecting the fact that the phosphorylation of STAT5 is To determine the mechanism by which pimozide decreases mediated by activated Jak2, the Jak2 inhibitor Jak inhibitor 1 also viable cell numbers, BAFEJ and HEL cells were treated with led to decreased phosphorylation of STAT5. STAT3 phosphoryla- pimozide for 24 h, after which they were permeabilized and tion was only minimally affected by pimozide (Figure 1a). Thus, stained with propidium iodide followed by flow cytometric & 2012 Macmillan Publishers Limited Leukemia (2012) 1402 -- 1448 Letters to the Editor 1408 Figure 1. Pimozide inhibits STAT5 phosphorylation, decreases expression of STAT5 target genes and reduces viability of MPN cells. (a) HEL cells were treated with vehicle, pimozide (10 mM) or Jak inhibitor 1 (1 mM) for 5 h. Immunoblots were performed with the indicated antibodies. (b) Peptide phosphorylation profiles of HEL cells treated with pimozide or JAK inhibitor 1. Relative phosphorylation of each peptide is shown compared with control (orange represents 0.99--0.75 activity, red represents 0.74--0.50 activity). (c) HEL cells were treated with vehicle, pimozide (10 mM) or Jak inhibitor 1 (1 mM) for 5 h, after which immunoblots were performed to phosphorylated MAP kinase and total MAP kinase. Normalized band intensities are indicated. (d) HEL cells were treated with vehicle, pimozide (10 mM) or Jak inhibitor 1 (0.8 mM) for 6 h, after which RNA was harvested, and expression of the indicated genes was measured using quantitative reverse transcriptase PCR and normalized to the expression of HPRT. (e) HEL cells were treated with pimozide or Jak inhibitor 1 at the indicated concentrations for 48 h, after which viable cell number was quantitated by ATP-dependent bioluminescence. roles performed both by mutated Jak2 and STAT5 in MPNs, we Table 1. Pimozide does not directly inhibit Jak tyrosine kinase activity hypothesized that dual inhibition of both Jak2 and STAT5 may lead to enhanced effects on myeloproliferative cells. When HEL Kinase % Inhibition of kinase activity cells were treated with pimozide or Jak inhibitor 1, each of the drugs alone led to a 50% reduction in tyrosine phosphorylation JAK1 6 JAK2 À3 of STAT5. However, when cells were treated with the combina- JAK2 JH1 JH2 À2 tion, there was near-complete loss of STAT5 phosphorylation JAK2 JH1 JH2 V617F À3 (Figure 2a). Reflecting this combinatorial effect on STAT5 JAK3 À7 phosphorylation, treatment of HEL cells with the combination of pimozide and Jak inhibitor 1 also led to a greater reduction in the The effect of pimozide on the activity of selected tyrosine kinases was level of the pro-survival protein Mcl1 (Figure 2b). It also led to a analyzed using the SelectScreen Kinase Profiling service. greater reduction in viable cells over a range of combinations in HEL cells as well as with the BAFEJ and SET2 cell lines (Figure 2c analysis.
Load more

Recommended publications
  • Mutation Analysis in Myeloproliferative Neoplasms AHS - M2101
    Corporate Medical Policy Mutation Analysis in Myeloproliferative Neoplasms AHS - M2101 File Name: mutation_analysis_in_myeloproliferative_neoplasms Origination: 1/1/2019 Last CAP review: 8/2021 Next CAP review: 8/2022 Last Review: 8/2021 Description of Procedure or Service Myeloproliferative neoplasms (MPN) are a heterogeneous group of clonal disorders characterized by overproduction of one or more differentiated myeloid lineages (Grinfeld, Nangalia, & Green, 2017). These include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The majority of MPN result from somatic mutations in the 3 driver genes, JAK2, CALR, and MPL, which represent major diagnostic criteria in combination with hematologic and morphological abnormalities (Rumi & Cazzola, 2017). Related Policies: BCR-ABL 1 Testing for Chronic Myeloid Leukemia AHS-M2027 ***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician. Policy BCBSNC will provide coverage for mutation analysis in myeloproliferative neoplasms when it is determined to be medically necessary because the medical criteria and guidelines shown below are met. Benefits Application This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy. When Mutation Analysis in Myeloproliferative Neoplasms is covered 1. JAK2, CALR or MPL mutation testing is considered medically necessary for the diagnosis of patients presenting with clinical, laboratory, or pathological findings suggesting classic forms of myeloproliferative neoplasms (MPN), that is, polycythemia vera (PV), essential thrombocythemia (ET), or primary myelofibrosis (PMF) when ordered by a hematology and/or oncology specialist in the following situations: A.
    [Show full text]
  • Promoter Janus Kinase 3 Proximal Characterization and Analysis Of
    The Journal of Immunology Characterization and Analysis of the Proximal Janus Kinase 3 Promoter1 Martin Aringer,2*† Sigrun R. Hofmann,2* David M. Frucht,* Min Chen,* Michael Centola,* Akio Morinobu,* Roberta Visconti,* Daniel L. Kastner,* Josef S. Smolen,† and John J. O’Shea3* Janus kinase 3 (Jak3) is a nonreceptor tyrosine kinase essential for signaling via cytokine receptors that comprise the common ␥-chain (␥c), i.e., the receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. Jak3 is preferentially expressed in hemopoietic cells and is up-regulated upon cell differentiation and activation. Despite the importance of Jak3 in lymphoid development and immune function, the mechanisms that govern its expression have not been defined. To gain insight into this issue, we set out to characterize the Jak3 promoter. The 5؅-untranslated region of the Jak3 gene is interrupted by a 3515-bp intron. Upstream of this intron and the transcription initiation site, we identified an ϳ1-kb segment that exhibited lymphoid-specific promoter activity and was responsive to TCR signals. Truncation of this fragment revealed that core promoter activity resided in a 267-bp fragment that contains putative Sp-1, AP-1, Ets, Stat, and other binding sites. Mutation of the AP-1 sites significantly diminished, whereas mutation of the Ets sites abolished, the inducibility of the promoter construct. Chromatin immunoprecipitation assays showed that histone acetylation correlates with mRNA expression and that Ets-1/2 binds this region. Thus, transcription factors that bind these sites, especially Ets family members, are likely to be important regulators of Jak3 expression.
    [Show full text]
  • 942.Full.Pdf
    Original Article Opposite Effect of JAK2 on Insulin-Dependent Activation of Mitogen-Activated Protein Kinases and Akt in Muscle Cells Possible Target to Ameliorate Insulin Resistance Ana C.P. Thirone, Lellean JeBailey, Philip J. Bilan, and Amira Klip Many cytokines increase their receptor affinity for Janus kinases (JAKs). Activated JAK binds to signal transducers and activators of transcription, insulin receptor substrates olypeptides such as erythropoietin, prolactin, (IRSs), and Shc. Intriguingly, insulin acting through its leptin, angiotensin, growth hormone, most inter- own receptor kinase also activates JAK2. However, the leukins, and interferon-␥ bind to receptors that impact of such activation on insulin action remains un- Plack intrinsic kinase activity, recruiting and acti- known. To determine the contribution of JAK2 to insulin vating cytoplasmic tyrosine kinases of the Janus family signaling, we transfected L6 myotubes with siRNA against (JAK) consisting of JAK1, JAK2, JAK3, and Tyk2 (1–3). JAK2 (siJAK2), reducing JAK2 protein expression by 75%. Activated JAK phosphorylates tyrosine residues within Insulin-dependent phosphorylation of IRS1/2 and Shc was not affected by siJAK2, but insulin-induced phosphoryla- itself and the associated receptor forming high-affinity tion of the mitogen-activated protein kinases (MAPKs) binding sites for a variety of signaling proteins containing Src homology 2 and other phosphotyrosine-binding do- extracellular signal–related kinase, p38, and Jun NH2- terminal kinase and their respective upstream kinases mains, including signal transducers and activators of tran- MKK1/2, MKK3/6, and MKK4/7 was significantly lowered scription, insulin receptor substrates (IRSs), and the when JAK2 was depleted, correlating with a significant adaptor protein Shc (1–4).
    [Show full text]
  • Biomarker Testing in Non- Small Cell Lung Cancer (NSCLC)
    The biopharma business of Merck KGaA, Darmstadt, Germany operates as EMD Serono in the U.S. and Canada. Biomarker testing in non- small cell lung cancer (NSCLC) Copyright © 2020 EMD Serono, Inc. All rights reserved. US/TEP/1119/0018(1) Lung cancer in the US: Incidence, mortality, and survival Lung cancer is the second most common cancer diagnosed annually and the leading cause of mortality in the US.2 228,820 20.5% 57% Estimated newly 5-year Advanced or 1 survival rate1 metastatic at diagnosed cases in 2020 diagnosis1 5.8% 5-year relative 80-85% 2 135,720 survival with NSCLC distant disease1 Estimated deaths in 20201 2 NSCLC, non-small cell lung cancer; US, United States. 1. National Institutes of Health (NIH), National Cancer Institute. Cancer Stat Facts: Lung and Bronchus Cancer website. www.seer.cancer.gov/statfacts/html/lungb.html. Accessed May 20, 2020. 2. American Cancer Society. What is Lung Cancer? website. https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html. Accessed May 20, 2020. NSCLC is both histologically and genetically diverse 1-3 NSCLC distribution by histology Prevalence of genetic alterations in NSCLC4 PTEN 10% DDR2 3% OTHER 25% PIK3CA 12% LARGE CELL CARCINOMA 10% FGFR1 20% SQUAMOUS CELL CARCINOMA 25% Oncogenic drivers in adenocarcinoma Other or ADENOCARCINOMA HER2 1.9% 40% KRAS 25.5% wild type RET 0.7% 55% NTRK1 1.7% ROS1 1.7% Oncogenic drivers in 0% 20% 40% 60% RIT1 2.2% squamous cell carcinoma Adenocarcinoma DDR2 2.9% Squamous cell carcinoma NRG1 3.2% Large cell carcinoma
    [Show full text]
  • Kinase Inhibitors: an Introduction
    David Peters Baran Group Meeting Kinase Inhibitors: An Introduction 2/2/19 INTRODUCTION SIGNAL TRANSDUCTION KINASES ARE IMPORTANT IN HUMAN BIOLOGY/DISEASE: The process describing how a signal (chemical/physical) is transmitted through a - Kinases are a superfamily of proteins (5th largest in humans) cell ultimately resulting in a cellular response - 518 genes and 106 pseudogenes - Diverse in size, subunit structure, and cellular location RECEPTOR TRANSDUCERS EFFECTORS - ~260 residues make up their conserved catalytic core - dysregulation of kinases occurs in many diseases (cancer, inflamatory, degenerative, and autoimmune diseases) - signals can originate inside or outside the cell - 244 of the 518 map to disease loci - signals generally passed through a series of steps (signal transduction pathway) often consisting of multiple enzymes and messengers protein O - pathways open possibility for signal aplification (>1x106) kinase ATP + PROTEIN OH ADP + PROTEIN O P O - Extracellular signals transduced by RTKs, GPCR’s, guanlyl cyclases, or ligand-gated Ion channels O - Phosphorylation is the most prominent covalent modification/signal in KINASES INHIBITORS ARE IMPORTANT IN DISEASE THERAPY/RESEARCH: cellular regulation - currently 51 FDA approved small molecule kinase inhibitors - “converter enzymes” (protein kinases and phosphoprotein phosphorlyases) - 4 FDA approved antibody kinase inhibitors are regulated; conserve ATP/maintain desired target protein state - thousands of known inhibitors spanning the kinome - pathway ends by affecting biomolecule
    [Show full text]
  • Anti-Inflammatory Cytokines Hepatocyte Growth Factor and Interleukin-11 Are Over-Expressed in Polycythemia Vera and Contribute T
    Oncogene (2011) 30, 990–1001 & 2011 Macmillan Publishers Limited All rights reserved 0950-9232/11 www.nature.com/onc ORIGINAL ARTICLE Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F M Boissinot1,3,4, C Cleyrat1,3, M Vilaine1, Y Jacques1, I Corre1 and S Hermouet1,2 1INSERM UMR 892, Institut de Biologie, Centre Hospitalier Universitaire, Nantes, France and 2Laboratoire d’He´matologie, Institut de Biologie, Centre Hospitalier Universitaire, Nantes, France The V617F activating mutation of janus kinase 2 (JAK2), Keywords: Polycythemia vera; JAK2V617F; hepatocyte a kinase essential for cytokine signalling, characterizes growth factor (HGF); interleukin 11 (IL-11); interleukin Polycythemia vera (PV), one of the myeloproliferative 6 (IL-6); inflammation neoplasms (MPN). However, not all MPNs carry mutations of JAK2, and in JAK2-mutated patients, expression of JAK2V617F does not always result in clone expansion. In the present study, we provide evidence that Introduction inflammation-linked cytokines are required for the growth of JAK2V617F-mutated erythroid progenitors. In a first Myeloproliferative neoplasms (MPNs) constitute a series of experiments, we searched for cytokines over- group of three clonal diseases: Polycythemia vera expressed in PV using cytokine antibody (Ab) arrays, and (PV), essential thrombocythemia (ET) and primary enzyme-linked immunosorbent assays for analyses of myelofibrosis. About half of MPN patients present with serum and bone marrow (BM) plasma, and quantitative activating mutations in the janus kinase 2 (JAK2) gene, reverse transcription–PCRs for analyses of cells purified which encodes for a tyrosine kinase essential for the from PV patients and controls.
    [Show full text]
  • The Role of Signaling Pathways in the Development and Treatment of Hepatocellular Carcinoma
    Oncogene (2010) 29, 4989–5005 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 www.nature.com/onc REVIEW The role of signaling pathways in the development and treatment of hepatocellular carcinoma S Whittaker1,2, R Marais3 and AX Zhu4 1Dana-Farber Cancer Institute, Boston, MA, USA; 2The Broad Institute, Cambridge, MA, USA; 3Institute of Cancer Research, London, UK and 4Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA Hepatocellular carcinoma (HCC) is a highly prevalent, malignancy in adults (Pons-Renedo and Llovet, 2003). treatment-resistant malignancy with a multifaceted mole- For the vast majority of patients, HCC is a late cular pathogenesis. Current evidence indicates that during complication of chronic liver disease, and as such, is hepatocarcinogenesis, two main pathogenic mechanisms often associated with cirrhosis. The main risk factors for prevail: (1) cirrhosis associated with hepatic regeneration the development of HCC include infection with hepatitis after tissue damage caused by hepatitis infection, toxins B virus (HBV) or hepatitis C virus (HCV). Hepatitis (for example, alcohol or aflatoxin) or metabolic influ- infection is believed to be the main etiologic factor in ences, and (2) mutations occurring in single or multiple 480% of cases (Anzola, 2004). Other risk factors oncogenes or tumor suppressor genes. Both mechanisms include excessive alcohol consumption, nonalcoholic have been linked with alterations in several important steatohepatitis, autoimmune hepatitis, primary biliary cellular signaling pathways. These pathways are of cirrhosis, exposure to environmental carcinogens (parti- interest from a therapeutic perspective, because targeting cularly aflatoxin B) and the presence of various genetic them may help to reverse, delay or prevent tumorigenesis.
    [Show full text]
  • Epigenetic Gene Regulation by Janus Kinase 1 in Diffuse Large B-Cell Lymphoma
    Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma Lixin Ruia,b,c,1,2, Amanda C. Drennanb,c,1, Michele Ceribellia,1, Fen Zhub,c, George W. Wrightd, Da Wei Huanga, Wenming Xiaoe, Yangguang Lib,c, Kreg M. Grindleb,c,LiLub,c, Daniel J. Hodsona, Arthur L. Shaffera, Hong Zhaoa, Weihong Xua, Yandan Yanga, and Louis M. Staudta,2 aLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892; bDepartment of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705; cCarbone Cancer Center, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705; dBiometric Research Branch, DCTD, National Cancer Institute, NIH, Bethesda, MD 20892; and eDivision of Bioinformatics and Biostatistics, National Center for Toxicological Research/Food and Drug Administration, Jefferson, AR 72079 Contributed by Louis M. Staudt, September 29, 2016 (sent for review July 22, 2016; reviewed by Anthony R. Green and Ross L. Levine) Janus kinases (JAKs) classically signal by activating STAT transcription promote STAT dimerization, nuclear translocation, and binding factors but can also regulate gene expression by epigenetically to cis-regulatory elements to regulate transcription (15, 17). This phosphorylating histone H3 on tyrosine 41 (H3Y41-P). In diffuse large canonical JAK/STAT pathway is deregulated in several hemato- B-cell lymphomas (DLBCLs), JAK signaling is a feature of the activated logic malignancies (16). In DLBCL, STAT3 is activated in the B-cell (ABC) subtype and is triggered by autocrine production of IL-6 ABC subtype and regulates gene expression to promote the sur- and IL-10.
    [Show full text]
  • JAK3 Deficiency, (SCID T-B+)
    JAK3 deficiency, (SCID T-B+) Author: Professor Luigi D. Notarangelo1,2 Creation Date: November 2001 Update: January 2005 1member of the European editorial committee of Orphanet encyclopedia 2Department of Pediatrics, University of Brescia, Spedali Civil, 25123 Brescia, Italy. [email protected] Abstract Keywords Diagnosis criteria/definition Differential diagnosis Prevalence Clinical description Treatment Etiology Diagnostic methods Genetic counseling Antenatal diagnosis Unresolved questions References Abstract JAK3 (Janus Kinase 3) deficiency is an autosomal recessive form of severe combined immune deficiency (SCID). It is characterized by lack of circulating T and NK (Natural Killer) cells and normal number of B lymphocytes. The disease is due to mutations in the JAK3 gene encoding an intracellular tyrosine kinase that is physically and functionally coupled with several cytokine receptors. Identification of gene anomalies has allowed physicians to make the diagnosis (even prenatal), and may prompt novel forms of treatment based on gene therapy. Although a relatively low number of JAK3-deficient subjects have been diagnosed, JAK3 deficiency represents an important cause of autosomal recessive SCID in the United States and its prevalence in Europe appears to be even higher. However it is considered as a rare disease (incidence is between 1/100,000 and 1/1,000,000 live births). JAK3-deficient patients present with the classical clinical features of SCID in the first few months of life, i.e. chronic diarrhea, failure to thrive, recurrent respiratory infection and/or generalized infections from opportunistic pathogens, or signs of graft-versus-host reaction (skin rash, abnormalities of liver function, pancytopenia) from transplacental acquired maternal T cells.
    [Show full text]
  • Kinase-Targeted Cancer Therapies: Progress, Challenges and Future Directions Khushwant S
    Bhullar et al. Molecular Cancer (2018) 17:48 https://doi.org/10.1186/s12943-018-0804-2 REVIEW Open Access Kinase-targeted cancer therapies: progress, challenges and future directions Khushwant S. Bhullar1, Naiara Orrego Lagarón2, Eileen M. McGowan3, Indu Parmar4, Amitabh Jha5, Basil P. Hubbard1 and H. P. Vasantha Rupasinghe6,7* Abstract The human genome encodes 538 protein kinases that transfer a γ-phosphate group from ATP to serine, threonine, or tyrosine residues. Many of these kinases are associated with human cancer initiation and progression. The recent development of small-molecule kinase inhibitors for the treatment of diverse types of cancer has proven successful in clinical therapy. Significantly, protein kinases are the second most targeted group of drug targets, after the G-protein- coupled receptors. Since the development of the first protein kinase inhibitor, in the early 1980s, 37 kinase inhibitors have received FDA approval for treatment of malignancies such as breast and lung cancer. Furthermore, about 150 kinase-targeted drugs are in clinical phase trials, and many kinase-specific inhibitors are in the preclinical stage of drug development. Nevertheless, many factors confound the clinical efficacy of these molecules. Specific tumor genetics, tumor microenvironment, drug resistance, and pharmacogenomics determine how useful a compound will be in the treatment of a given cancer. This review provides an overview of kinase-targeted drug discovery and development in relation to oncology and highlights the challenges and future potential for kinase-targeted cancer therapies. Keywords: Kinases, Kinase inhibition, Small-molecule drugs, Cancer, Oncology Background Recent advances in our understanding of the fundamen- Kinases are enzymes that transfer a phosphate group to a tal molecular mechanisms underlying cancer cell signaling protein while phosphatases remove a phosphate group have elucidated a crucial role for kinases in the carcino- from protein.
    [Show full text]
  • Advances in Systemic Therapy for HER2-Positive Metastatic Breast Cancer Phuong Khanh H Morrow1, Francisco Zambrana1,2 and Francisco J Esteva1
    Available online http://breast-cancer-research.com/content/11/4/207 Review Advances in systemic therapy for HER2-positive metastatic breast cancer Phuong Khanh H Morrow1, Francisco Zambrana1,2 and Francisco J Esteva1 1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Holcombe Boulevard, Houston, TX 77030, USA 2Current address: Department of Medical Oncology, Hospital Infanta Sofia, Paseo de Europa, 34, Madrid 28702, Spain Corresponding author: Phuong Khanh H Morrow, [email protected] Published: 15 July 2009 Breast Cancer Research 2009, 11:207 (doi:10.1186/bcr2324) This article is online at http://breast-cancer-research.com/content/11/4/207 © 2009 BioMed Central Ltd Abstract differentiation, survival, and migration that are associated with Human epidermal growth factor receptor (HER)2 over-expression HER2-positive breast cancers (Figure 1). Thus, women with is associated with a shortened disease-free interval and poor HER2-positive breast cancers exhibit significantly decreased survival. Although the addition of trastuzumab to chemotherapy in disease-free survival and overall survival (OS) [2-5]. the first-line setting has improved response rates, progression-free survival, and overall survival, response rates declined when trastu- This review discusses progress in the treatment of HER2- zumab was used beyond the first-line setting because of multiple positive metastatic breast cancer since the discovery of the mechanisms of resistance. Studies have demonstrated the clinical utility of continuing
    [Show full text]
  • Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia
    cancers Review Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia Kalpana K. Bhanumathy 1,*, Amrutha Balagopal 1, Frederick S. Vizeacoumar 2 , Franco J. Vizeacoumar 1,3, Andrew Freywald 2 and Vincenzo Giambra 4,* 1 Division of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; [email protected] (A.B.); [email protected] (F.J.V.) 2 Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; [email protected] (F.S.V.); [email protected] (A.F.) 3 Cancer Research Department, Saskatchewan Cancer Agency, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada 4 Institute for Stem Cell Biology, Regenerative Medicine and Innovative Therapies (ISBReMIT), Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, FG, Italy * Correspondence: [email protected] (K.K.B.); [email protected] (V.G.); Tel.: +1-(306)-716-7456 (K.K.B.); +39-0882-416574 (V.G.) Simple Summary: Protein phosphorylation is a key regulatory mechanism that controls a wide variety of cellular responses. This process is catalysed by the members of the protein kinase su- perfamily that are classified into two main families based on their ability to phosphorylate either tyrosine or serine and threonine residues in their substrates. Massive research efforts have been invested in dissecting the functions of tyrosine kinases, revealing their importance in the initiation and progression of human malignancies. Based on these investigations, numerous tyrosine kinase inhibitors have been included in clinical protocols and proved to be effective in targeted therapies for various haematological malignancies.
    [Show full text]